• Ruth L. Kirschstein National Research Service Awards (NRSA) Predoctoral Stipends, Training Related Expenses, Institutional Allowance, and Tuition/Fees Effective for Fiscal Year 2017  
(NOT-OD-17-072)  
National Institutes of Health, Agency for Healthcare Research and Quality
• Extramural Loan Repayment Program for Clinical Researchers (LRP-CR)  
(NOT-OD-17-077)  
National Institutes of Health
• Extramural Loan Repayment Program for Pediatric Research (LRP-PR)  
(NOT-OD-17-078)  
National Institutes of Health
• Extramural Loan Repayment Program for Health Disparities Research (LRP-HDR)  
(NOT-OD-17-080)  
National Institutes of Health
• Extramural Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds (LRP-IDB)  
(NOT-OD-17-081)  
National Institutes of Health
• Protecting Life in Global Health Assistance  
(NOT-OD-17-083)  
National Institutes of Health
• Notice of Correction to Eligibility of Foreign Institutions for PA-17-120, "Discovering Novel Targets: The Molecular Genetics of Drug Addiction and Related Co-Morbidities (R01)"  
(NOT-DA-17-045)  
National Institute on Drug Abuse
• Notice of NIDCR's Withdrawal from Participation in PAR-16-242 "Bioengineering Research Grants (BRG) (R01)"  
(NOT-DE-17-010)  
National Institute of Dental and Craniofacial Research
• Notice of NIDCR's Withdrawal from Participation in PA-16-040 "Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21)"  
(NOT-DE-17-011)  
National Institute of Dental and Craniofacial Research
• Notice of Intent to Publish a Funding Opportunity Announcement for Point of Care Technologies Research Network Centers (U54)  
(NOT-EB-17-004)  
National Institute of Biomedical Imaging and Bioengineering, John E. Fogarty International Center, National Center for Complementary and Integrative Health, National Heart, Lung, and Blood Institute, National Institute on Aging, Office of Behavioral and Social Science Research
• The NIH Common Fund Regenerative Medicine Program (RMP) Announces the Opportunity to Collaborate with the Stem Cell Translation Laboratory (SCTL) at the National Center for Advancing Translational Sciences (NCATS)  
(NOT-RM-17-030)  
NIH Roadmap Initiatives, National Center for Advancing Translational Sciences, The Common Fund/Office of Strategic Coordination
• Notice Announcing Funding Opportunity Issued for the NIH Data Commons Pilot Phase  
(NOT-RM-17-031)  
NIH Roadmap Initiatives  
The Common Fund/Office of Strategic Coordination
• Revision: Notice of Extension of Effective Date for Final NIH Policy on the Use of Single Institution Review Board for Multi-Site Research  
(NOT-OD-17-076)  
National Institutes of Health
• Notice of Change to Key Dates in PA-16-373 "Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R21)"  
(NOT-AI-17-029)  
National Institute of Allergy and Infectious Diseases
• Notice of Change to Key Dates in PA-16-372 "Small Grants on Primary Immunodeficiency Diseases (R03)"  
(NOT-AI-17-030)  
National Institute of Allergy and Infectious Diseases
• Notice of Pre-Application Webinar for RFA-AR-18-004, NIAMS Rheumatic Diseases Research Resource-based Centers  
(NOT-AR-17-017)  
National Institute of Arthritis and Musculoskeletal and Skin Diseases
• Notice of Pre-application Webinar for PAR-16-166 "Integrating Biospecimen Science Approaches into Clinical Assay Development (U01)"  
(NOT-CA-17-068)  
National Cancer Institute
• Notice of Additional Receipt Date for PAR-17-270 "NIDDK Central Repositories Non-renewable Sample Access (X01)"  
(NOT-DK-17-013)  
National Institute of Diabetes and Digestive and Kidney Diseases
- Extend Application Deadline—Creation and Implementation of the National Evaluation System for Health Technology (NEST) Coordination Center (CC)  
  [NOT-FD-18-001]  
  Food and Drug Administration

- Clarification of NHLBI Policy Regarding Submission of Phase II and Beyond Clinical Trials Applications  
  [NOT-HL-17-519]  
  National Heart, Lung, and Blood Institute

- Notice of Interest to Highlight High-Priority Time-Sensitive Research Opportunities Toward Zero Suicide Healthcare Systems  
  [NOT-MH-17-031]  
  National Institute of Mental Health

- Notice of Change in Expiration Date and Application Due Date for PAR-16-155 "NeuroNEXT Clinical Trials (U01)"  
  [NOT-NS-17-034]  
  National Institute of Neurological Disorders and Stroke

- Notice of Availability of Administrative Supplements for CTSA Awardees: Development of Resources to Facilitate Single IRB Review for Multi-Site Research  
  [NOT-TR-17-018]  
  National Center for Advancing Translational Sciences

- Request for Information (RFI): National Institute on Alcohol Abuse and Alcoholism (NIAAA) Initiative for Collecting, Archiving, and Sharing Individual-Level Human Subjects Data  
  [NOT-AA-17-005]  
  National Institute on Alcohol Abuse and Alcoholism

- Notice of Clarification to Award Budget Instructions for PA-17-138 "Administrative Supplements to Promote Research Collaborations on Fusion Oncoproteins as Drivers of Childhood Cancer (Admin Supp)"  
  [NOT-CA-17-066]  
  National Cancer Institute

- Notice of Availability of Administrative Supplements to NIBIB Grants: Technologies to Catalyze New Discoveries in Alzheimer's Disease and Related Dementias  
  [NOT-EB-17-002]  
  National Institute of Biomedical Imaging and Bioengineering, National Institute on Aging

- Notice of NICHD's Participation in PAR-16-297 Native American Research Centers for Health (NARCH) (S06)  
  [NOT-HD-17-013]  
  Eunice Kennedy Shriver National Institute of Child Health and Human Development

- Notice of NHLBI Participation in PA-17-286 "Administrative Supplements for Participation in the Concept to Clinic: Commercializing Innovation (C3i) Program (Admin Supp)"  
  [NOT-HL-17-517]  
  National Heart, Lung, and Blood Institute

- Notice of Intent to Publish a Funding Opportunity Announcement for NINR Exploratory Centers (P20)  
  [NOT-NR-17-018]  
  National Institute of Nursing Research

- Notice of Intent to Publish a Funding Opportunity Announcement for NINR Centers of Excellence (P30)  
  [NOT-NR-17-019]  
  National Institute of Nursing Research

- Notice of Expiration of RFA-NS-17-008 "BRAIN Initiative: SBIR Direct to Phase II Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (U44)"  
  [NOT-NS-17-028]  
  National Institute of Neurological Disorders and Stroke

- Notice of Change in Application Due Dates for PAR-17-277 "NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke, Treatment, Recovery and Resource Access (X01)"  
  [NOT-NS-17-032]  
  National Institute of Neurological Disorders and Stroke

- Notice of Change in Eligibility Requirements for PAR-17-002 "International Research Scientist Development Award (IRSDA) (K01)"  
  [NOT-TW-17-005]  
  John E. Fogarty International Center

- Additional Change to the NIH/AHRQ/NIOSH Policy on Post-Submission Materials  
  [NOT-OD-17-066]  
  National Institutes of Health

- Correction: Maximum Direct Costs for Applications Submitted in Response to PAR-16-369 "Resource-Related Research Projects for Development of Animal Models and Related Materials (R24)"  
  [NOT-OD-17-067]  
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

- Reminder: Authentication of Key Biological and/or Chemical Resources  
  [NOT-OD-17-068]  
  National Institutes of Health, Agency for Healthcare Research and Quality
REQUEST FOR APPLICATIONS

**TITLE:** Pediatric Early Phase Clinical Trials Network (UM1)  
(RFA-CA-17-027)

**SPONSOR:** National Cancer Institute

**Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to enhance NCI's program for conducting early phase clinical trials in children with cancer, currently supported as the Children's Oncology Group (COG) Phase 1 & Pilot Consortium. The overall goal is to ensure that high priority novel agents can be tested in pediatric patients in a timely manner. Towards this end, applications are solicited for the Pediatric Early Phase Clinical Trials Network (PEP-CTN) to continue the clinical research activities now supported through the COG Phase 1 & Pilot Consortium. The scope of the proposed PEP-CTN should cover the design and conduct of pediatric Phase 1 trials that will be expected to often include Phase 2 expansion cohorts. In addition, the Network will be expected to conduct pilot studies of novel regimens to determine their tolerability so that promising agents/regimens can proceed to definitive testing in Phase 3 clinical trials. These clinical trials should meaningfully advance pediatric oncology drug development during the award period. The awardee will lead the PEP-CTN Operations and Data/Statistics Center (ODSC) and will interact with selected Core Member institutions and Phase 2 Expansion Institutions on the conduct of early phase clinical trials. This FOA is designed to enhance the existing program so that the Network can more efficiently and expeditiously develop and implement state-of-the-art early phase clinical trials. The important changes include: Recognition of the need for seamless transitions from Phase 1 to Phase 2 testing, reflected by the modified initiative name (PEP-CTN) emphasizing "early phase" clinical trials; The establishment of the Pediatric Early Phase (PEP) Agent Prioritization Committee to prioritize agents for evaluation by the PEP-CTN and to expedite the pace at which novel investigational agents enter clinical testing in pediatric patients; The addition of central monitoring for all PEP-CTN clinical trials; and Funds to support genomic characterization to establish eligibility and/or treatment assignment for PEP-CTN clinical trials and/or to facilitate factors determining the activity of agents studied by the PEP-CTN. Applicants responding to this FOA must base their plans for the PEP-CTN institutional accrual base for Network clinical trials on the NCI's intention to include the current member institutions of the COG Phase 1/Pilot Consortium as the PEP-CTN Core Member Institutions. An additional 20 institutions are expected to be selected post-award to participate in Network clinical trials when additional accrual potential is needed (e.g., for Phase 2 expansion cohorts).

Application Receipt Date(s): August 16, 2017
**TITLE:** AHRQ National Research Service Award (NRSA) Institutional Research Training Grant (T32) (RFA-HS-17-011)

**SPONSOR:** Agency for Healthcare Research and Quality

**Synopsis:** The Agency for Healthcare Research and Quality (AHRQ) will award National Research Service Award (NRSA) Institutional Research Training Grants (T32) to eligible domestic institutions to enhance predoctoral and postdoctoral research training and ensure that a diverse and highly trained workforce is available and committed to the generation, translation and dissemination of new scientific evidence and analytical tools that will be used to improve health care delivery in the United States. Research training programs will incorporate didactic, research and career development elements to prepare individuals for careers that will have a significant impact on the health care needs of the Nation.

Application Receipt Date(s): September 12, 2017

---

**PROGRAM ANNOUNCEMENTS**

**TITLE:** Integration of Individual Residential Histories into Cancer Research (R21) (PA-17-295)

**SPONSOR:** National Cancer Institute

**Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to support substantive investigation of the role of individual residential histories in cancer etiology and outcomes, and to encourage the development of complex analytical strategies in support of substantive investigation.

Application Receipt/Submission Date(s): Multiple dates, see announcement

**TITLE:** Integration of Individual Residential Histories into Cancer Research (R01) (PA-17-298)

**SPONSOR:** National Cancer Institute

**Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to support substantive investigation of the role of individual residential histories in cancer etiology and outcomes, and to encourage the development of complex analytical strategies in support of substantive investigation.

Application Receipt/Submission Date(s): Multiple dates, see announcement

**TITLE:** NCCIH Natural Product Phase I-IIa Clinical Trial Award (R33) (PAR-17-318)

**SPONSOR:** National Center for Complementary and Integrative Health

Application Receipt/Submission Date(s): New Applications: October 4, 2017 Resubmission and Revision Applications: October 24, 2017

**TITLE:** NCCIH Natural Product Phase I-IIa Clinical Trial Phased Innovation Award (R61/R33) (PAR-17-319)

**SPONSOR:** National Center for Complementary and Integrative Health

Application Receipt/Submission Date(s): New Applications: October 4, 2017 Resubmission and Revision Applications: October 24, 2017

**TITLE:** PHS 2017-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44]) (PA-17-302)

**SPONSOR:** National Institutes of Health

Center for Biologics Evaluation and Research
Office of Foods and Veterinary Medicine/Center for Food Safety and Applied Nutrition
Food and Drug Administration
National Center for Advancing Translational Sciences
National Center for Complementary and Integrative Health

**National Cancer Institute**

National Eye Institute
National Human Genome Research Institute
National Heart, Lung, and Blood Institute
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
National Institute of Allergy and Infectious Diseases
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institute of Biomedical Imaging and Bioengineering

**Eunice Kennedy Shriver National Institute of Child Health and Human Development**

National Institute on Drug Abuse
National Institute on Deafness and Other Communication Disorders
National Institute of Dental and Craniofacial Research
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of Environmental Health Sciences
National Institute of General Medical Sciences
National Institute of Mental Health
Synopsis: This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH, CDC, and FDA awarding components identified in this FOA are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2017-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA).

Application Receipt/Submission Date(s): Multiple dates, see announcement

• TITLE: PHS 2017-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
(PA-17-303)
SPONSOR: National Institutes of Health
National Center for Advancing Translational Sciences
National Center for Complementary and Integrative Health
National Cancer Institute
National Eye Institute
National Human Genome Research Institute
National Heart, Lung, and Blood Institute
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
National Institute of Allergy and Infectious Diseases
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institute of Biomedical Imaging and Bioengineering
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Drug Abuse
National Institute on Deafness and Other Communication Disorders
National Institute of Dental and Craniofacial Research
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of Environmental Health Sciences
National Institute of General Medical Sciences
National Institute of Mental Health
National Institute on Minority Health and Health Disparities
National Institute of Neurological Disorders and Stroke
National Institute of Nursing Research
National Library of Medicine
Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
Synopsis: This Funding Opportunity Announcement (FOA) issued by the National Institutes of Health (NIH) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH awarding components identified in this FOA are encouraged to submit STTR grant applications in response to identified topics (see PHS 2017-2 SBIR/STTR Program Descriptions and Research Topics for NIH).

Application Receipt/Submission Date(s): Multiple dates, see announcement

• TITLE: NeuroNEXT Small Business Innovation in Clinical Trials (U44)
(PAR-17-300)
SPONSOR: National Institute of Neurological Disorders and Stroke
Application Receipt/Submission Date(s): Multiple dates, see announcement

• TITLE: Limited Competition: Small Grant Program for ORIP Special Emphasis Research Career Award (SERCA) K01 Recipients (R03)
(PAR-17-301)
SPONSOR: Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
Application Receipt/Submission Date(s): Multiple dates, see announcement

• TITLE: Institutional Development Award (IDeA) Program Infrastructure for Clinical and Translational Research (IDeA-CTR)(U54)
(PAR-17-304)
SPONSOR: National Institute of General Medical Sciences
Application Receipt/Submission Date(s): Multiple dates, see announcement

• TITLE: U.S. Tobacco Control Policies to Reduce Health Disparities (R01)
(PAR-17-217)
SPONSOR: National Cancer Institute
Synopsis: The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing health disparities in tobacco use in the United States. Specifically, this FOA is intended to stimulate scientific inquiry focused on innovative tobacco control policies. Applicants may propose projects in which the primary outcome of interest is on reducing tobacco use health disparities in vulnerable populations by utilizing tobacco prevention and control strategies. The long-term goal of this FOA is to reduce health disparities in health outcomes thereby reducing the excess disease burden of tobacco use within these groups. Applicants submitting applications related to health economics are encouraged to consult NOT-OD-16-025 to ensure that applications align with NIH mission priorities in health economics research.

Application Receipt/Submission Date(s): Multiple dates, see announcement

- **TITLE:** U.S. Tobacco Control Policies to Reduce Health Disparities (R21)
  - (PAR-17-218)
  - **SPONSOR:** National Cancer Institute

  Synopsis: The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing health disparities in tobacco use in the United States. Specifically, this FOA is intended to stimulate scientific inquiry focused on innovative tobacco control policies. Applicants may propose projects in which the primary outcome of interest is on reducing tobacco use health disparities in vulnerable populations by utilizing tobacco prevention and control strategies. The long-term goal of this FOA is to reduce health disparities in health outcomes thereby reducing the excess disease burden of tobacco use within these groups. Applicants submitting applications related to health economics are encouraged to consult NOT-OD-16-025 to ensure that applications align with NIH mission priorities in health economics research.

  Application Receipt/Submission Date(s): Multiple dates, see announcement

OTHER FUNDING OPPORTUNITIES
(Sponsors in bold are NIH Peer Reviewed Organizations)

- **TITLE:** Research on Chronic Overlapping Pain Conditions (R21)
  - **SPONSOR:** United States Department of Health and Human Services (HHS), National Institutes of Health (NIH)

  Synopsis: The purpose of this Funding Opportunity Announcement (FOA) is to encourage epidemiological, clinical and translational research that will increase our understanding of the natural history, prevalence, biological mechanisms, psychological variables, and clinical risk factors responsible for the presence of multiple chronic pain conditions in people with pain. Recent clinical findings suggest that substantial overlap may exist between chronic pain conditions. Individuals diagnosed with one disorder often exhibit characteristics of additional chronic painful conditions or transition to other diagnostic categories. A better understanding is needed of the prevalence of overlapping pain conditions, the underlying etiologies, the progression of these conditions, the evolution of these overlaps, and the therapeutic approaches best suited for treating subjects with these conditions. The main objective of this FOA is the formation of research groups with interests bridging expertise in pain mechanisms with translational and clinical expertise to address important unresolved questions about overlapping pain conditions. Applicants are encouraged to leverage existing and develop new resources pertinent to the study of these conditions. Applicants are encouraged to include researchers with complementary expertise from outside the pain field in their research teams who will enhance the breadth of research and understanding of comorbid chronic pain conditions.

- **TITLE:** Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research
  - [http://www.aacr.org/Research/Awards/Pages/Awards-Detail.aspx?ItemId=11#.VcISoWfJVXl](http://www.aacr.org/Research/Awards/Pages/Awards-Detail.aspx?ItemId=11#.VcISoWfJVXl)
  - **SPONSOR:** American Association for Cancer Research (AACR)

  Synopsis: This award recognizes a true champion of cancer research, an individual who embodies the sustained commitment of Margaret Foti to the prevention and cure of cancer. The award is given to an individual whose leadership and extraordinary achievements in cancer research or in support of cancer research have made a major impact on the field. Such achievements include contributions to the acceleration of progress in cancer research, raising national or international awareness of cancer research, or other demonstrations of a sustained commitment to the conquest of cancer.

- **TITLE:** AACR-CRI Lloyd J. Old Award in Cancer Immunology
  - [http://www.aacr.org/Research/Awards/Pages/Awards-Detail.aspx?ItemId=2](http://www.aacr.org/Research/Awards/Pages/Awards-Detail.aspx?ItemId=2)
  - **SPONSOR:** American Association for Cancer Research (AACR)

  Synopsis: The Award in Cancer Immunology was established to honor the memory of the late Lloyd J. Old and will recognize an active scientist whose outstanding and innovative research in cancer immunology has had a far-reaching impact on the cancer field.

- **TITLE:** AACR Scientific Achievement Awards - AACR G.H.A. Clowes Memorial Award
  - [http://www.aacr.org/Research/Awards/Pages/Awards-Detail.aspx?ItemId=5](http://www.aacr.org/Research/Awards/Pages/Awards-Detail.aspx?ItemId=5)
  - **SPONSOR:** American Association for Cancer Research (AACR)

  Synopsis: The award recognizes an individual with outstanding recent accomplishments in basic cancer research. The AACR and Eli Lilly and Company established this award in 1961 to honor Dr. G.H.A. Clowes, who was a founding member of the AACR and a research director of Eli Lilly.
The Patient-Centered Outcomes Research Institute (PCORI) is launching this research initiative to generate needed scientific evidence to aid patients, caregivers, and providers in decision making about the clinical options for symptom management in advanced illness. PCORI seeks to fund multiple high-quality clinical studies comparing evidence-based pharmacological and non-pharmacological treatments for the range of symptoms experienced by patients with advanced illness.

**Synopsis:** The Patient-Centered Outcomes Research Institute (PCORI) is seeking proposals that will aid clinical decision making for symptom management for patients living with advanced illness. PCORI seeks to fund multiple high-quality clinical studies comparing evidence-based pharmacological and non-pharmacological treatments for the range of symptoms experienced by patients with advanced illness.

**SPONSOR:** Patient-Centered Outcomes Research Institute (PCORI)
should be submitted within 40 days of receiving the invitation. Full proposals will be reviewed within 40 days of submission.

• **TITLE:** Engagement Award (EAIN): Research Meeting and Conference Support
  **SPONSOR:** Patient-Centered Outcomes Research Institute (PCORI)
  **Synopsis:** This Engagement Award Initiative Notice, Patient-Centered Outcomes Research/Clinical Comparative Effectiveness Research Meeting and Conference Support, includes guidelines for available funding support for meetings and conferences that align with PCORI’s Mission and Strategic Plan and facilitate expansion of patient-centered outcomes research/Clinical comparative effectiveness research (PCOR/CER).

• **TITLE:** Research on Chronic Overlapping Pain Conditions (R21)
  **SPONSOR:** United States Department of Health and Human Services (HHS), National Institutes of Health (NIH)
  **Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to encourage epidemiological, clinical and translational research that will increase our understanding of the natural history, prevalence, biological mechanisms, psychological variables, and clinical risk factors responsible for the presence of multiple chronic pain conditions in people with pain. Recent clinical findings suggest that substantial overlap may exist between chronic pain conditions. Individuals diagnosed with one disorder often exhibit characteristics of additional chronic painful conditions or transition to other diagnostic categories. A better understanding is needed of the prevalence of overlapping pain conditions, the underlying etiologies, the progression of these conditions, the evolution of these overlaps, and the therapeutic approaches best suited for treating subjects with these conditions. The main objective of this FOA is the formation of research groups with interests bridging expertise in pain mechanisms with translational and clinical expertise to address important unresolved questions about overlapping pain conditions. Applicants are encouraged to leverage existing and develop new resources pertinent to the study of these conditions. Applicants are encouraged to include researchers with complementary expertise from outside the pain field in their research teams who will enhance the breadth of research and understanding of comorbid chronic pain conditions.

• **TITLE:** Peer Reviewed Medical Research Program (PRMRP): Investigator-Initiated Research Award
  **SPONSOR:** United States Department of Defense (DOD), Department of the Army, U.S. Army Medical Research and Materiel Command (USAMRMC), Office of Congressionally Directed Medical Research Programs (CDMRP) (NIH)
  **Synopsis:** The vision of the FY17 PRMRP is to improve the health and well-being of all military Service members, Veterans, and beneficiaries. The PRMRP challenges the scientific and clinical communities to address at least one of the FY17 Topic Areas with original ideas that foster new directions along the entire spectrum of research and clinical care. The program seeks applications in laboratory, clinical, behavioral, epidemiologic, and other areas of research to advance knowledge in disease etiology, improve prevention, detection, diagnosis, treatment, and quality of life for those affected by a relevant disease or condition, and to develop and validate clinical care or public health guidelines.

• **TITLE:** Circle of Life Awards: Celebrating Innovation in Palliative and End-of-Life Care
  [http://www.aha.org/about/awards/col/index.shtml](http://www.aha.org/about/awards/col/index.shtml)
  **SPONSOR:** American Hospital Association (AHA)